CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury

Stephanie M. Williams, Carrie Peltz, Kristine Yaffe, Philip Schulz, Michael Sierks

Research output: Contribution to journalArticle

Abstract

RESULTS: Each of the 11 scFvs individually could significantly distinguish between TBI and control samples, though they did not detect each TBI sample. Comparing the levels of all 11 variants, all 25 TBI cases displayed higher reactivity compared to the controls and receiver operating characteristic analysis revealed 100% sensitivity and specificity. Higher total protein variants levels correlated with TBI severity and with loss of consciousness. Oligomeric tau levels distinguished between single and multiple TBI incidents. While all TBI cases were readily selected with the panel, the binding pattern varied from patient to patient, suggesting subgroups that are at increased risk for different neurodegenerative diseases.

CONCLUSION: The panel of protein variants-specific scFvs can be used to identify blood-based biomarkers indicative of TBI even 20 years or more after the initial TBI. Being able to identify subgroups of biomarker profiles allows for the possibility of individually targeted treatments.

OBJECTIVE: To utilize a panel of 11 single chain variable fragments (scFvs) that selectively bind disease-related variants of TAR DNA-binding protein (TDP)-43, β-amyloid, tau, and α-synuclein to assess damage following traumatic brain injury (TBI), and determine if the presence of protein variants could account for the increased risk of various neurodegenerative diseases following TBI.

METHODS: We utilized the panel of 11 scFvs in a sensitive ELISA format to analyze sera from 43 older veterans, 25 who had experienced at least 1 TBI incident during their lifetime (∼29.4 years after TBI), and 18 controls who did not incur TBI, in a cross-sectional study.

Original languageEnglish (US)
Pages (from-to)702-709
Number of pages8
JournalNeurology
Volume91
Issue number15
DOIs
StatePublished - Oct 9 2018

Fingerprint

Central Nervous System Diseases
Biomarkers
Proteins
Neurodegenerative Diseases
Traumatic Brain Injury
Synucleins
Single-Chain Antibodies
Unconsciousness
DNA-Binding Proteins
Veterans
Amyloid
ROC Curve
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury. / Williams, Stephanie M.; Peltz, Carrie; Yaffe, Kristine; Schulz, Philip; Sierks, Michael.

In: Neurology, Vol. 91, No. 15, 09.10.2018, p. 702-709.

Research output: Contribution to journalArticle

Williams, Stephanie M. ; Peltz, Carrie ; Yaffe, Kristine ; Schulz, Philip ; Sierks, Michael. / CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury. In: Neurology. 2018 ; Vol. 91, No. 15. pp. 702-709.
@article{dc8289182776448b848b19fe58b2a948,
title = "CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury",
abstract = "RESULTS: Each of the 11 scFvs individually could significantly distinguish between TBI and control samples, though they did not detect each TBI sample. Comparing the levels of all 11 variants, all 25 TBI cases displayed higher reactivity compared to the controls and receiver operating characteristic analysis revealed 100{\%} sensitivity and specificity. Higher total protein variants levels correlated with TBI severity and with loss of consciousness. Oligomeric tau levels distinguished between single and multiple TBI incidents. While all TBI cases were readily selected with the panel, the binding pattern varied from patient to patient, suggesting subgroups that are at increased risk for different neurodegenerative diseases.CONCLUSION: The panel of protein variants-specific scFvs can be used to identify blood-based biomarkers indicative of TBI even 20 years or more after the initial TBI. Being able to identify subgroups of biomarker profiles allows for the possibility of individually targeted treatments.OBJECTIVE: To utilize a panel of 11 single chain variable fragments (scFvs) that selectively bind disease-related variants of TAR DNA-binding protein (TDP)-43, β-amyloid, tau, and α-synuclein to assess damage following traumatic brain injury (TBI), and determine if the presence of protein variants could account for the increased risk of various neurodegenerative diseases following TBI.METHODS: We utilized the panel of 11 scFvs in a sensitive ELISA format to analyze sera from 43 older veterans, 25 who had experienced at least 1 TBI incident during their lifetime (∼29.4 years after TBI), and 18 controls who did not incur TBI, in a cross-sectional study.",
author = "Williams, {Stephanie M.} and Carrie Peltz and Kristine Yaffe and Philip Schulz and Michael Sierks",
year = "2018",
month = "10",
day = "9",
doi = "10.1212/WNL.0000000000006322",
language = "English (US)",
volume = "91",
pages = "702--709",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury

AU - Williams, Stephanie M.

AU - Peltz, Carrie

AU - Yaffe, Kristine

AU - Schulz, Philip

AU - Sierks, Michael

PY - 2018/10/9

Y1 - 2018/10/9

N2 - RESULTS: Each of the 11 scFvs individually could significantly distinguish between TBI and control samples, though they did not detect each TBI sample. Comparing the levels of all 11 variants, all 25 TBI cases displayed higher reactivity compared to the controls and receiver operating characteristic analysis revealed 100% sensitivity and specificity. Higher total protein variants levels correlated with TBI severity and with loss of consciousness. Oligomeric tau levels distinguished between single and multiple TBI incidents. While all TBI cases were readily selected with the panel, the binding pattern varied from patient to patient, suggesting subgroups that are at increased risk for different neurodegenerative diseases.CONCLUSION: The panel of protein variants-specific scFvs can be used to identify blood-based biomarkers indicative of TBI even 20 years or more after the initial TBI. Being able to identify subgroups of biomarker profiles allows for the possibility of individually targeted treatments.OBJECTIVE: To utilize a panel of 11 single chain variable fragments (scFvs) that selectively bind disease-related variants of TAR DNA-binding protein (TDP)-43, β-amyloid, tau, and α-synuclein to assess damage following traumatic brain injury (TBI), and determine if the presence of protein variants could account for the increased risk of various neurodegenerative diseases following TBI.METHODS: We utilized the panel of 11 scFvs in a sensitive ELISA format to analyze sera from 43 older veterans, 25 who had experienced at least 1 TBI incident during their lifetime (∼29.4 years after TBI), and 18 controls who did not incur TBI, in a cross-sectional study.

AB - RESULTS: Each of the 11 scFvs individually could significantly distinguish between TBI and control samples, though they did not detect each TBI sample. Comparing the levels of all 11 variants, all 25 TBI cases displayed higher reactivity compared to the controls and receiver operating characteristic analysis revealed 100% sensitivity and specificity. Higher total protein variants levels correlated with TBI severity and with loss of consciousness. Oligomeric tau levels distinguished between single and multiple TBI incidents. While all TBI cases were readily selected with the panel, the binding pattern varied from patient to patient, suggesting subgroups that are at increased risk for different neurodegenerative diseases.CONCLUSION: The panel of protein variants-specific scFvs can be used to identify blood-based biomarkers indicative of TBI even 20 years or more after the initial TBI. Being able to identify subgroups of biomarker profiles allows for the possibility of individually targeted treatments.OBJECTIVE: To utilize a panel of 11 single chain variable fragments (scFvs) that selectively bind disease-related variants of TAR DNA-binding protein (TDP)-43, β-amyloid, tau, and α-synuclein to assess damage following traumatic brain injury (TBI), and determine if the presence of protein variants could account for the increased risk of various neurodegenerative diseases following TBI.METHODS: We utilized the panel of 11 scFvs in a sensitive ELISA format to analyze sera from 43 older veterans, 25 who had experienced at least 1 TBI incident during their lifetime (∼29.4 years after TBI), and 18 controls who did not incur TBI, in a cross-sectional study.

UR - http://www.scopus.com/inward/record.url?scp=85054776525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054776525&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000006322

DO - 10.1212/WNL.0000000000006322

M3 - Article

C2 - 30297502

AN - SCOPUS:85054776525

VL - 91

SP - 702

EP - 709

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 15

ER -